HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

darapladib

a selective lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor, on biomarkers of cardiovascular (CV) risk
Networked: 50 relevant articles (3 outcomes, 31 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Serruys, Patrick W: 6 articles (01/2015 - 09/2008)
2. White, Harvey D: 4 articles (09/2014 - 04/2011)
3. Tarka, Elizabeth: 4 articles (09/2014 - 10/2010)
4. Cannon, Christopher P: 4 articles (09/2014 - 10/2010)
5. Mohler, Emile R: 4 articles (05/2014 - 04/2008)
6. Zalewski, Andrew: 4 articles (05/2011 - 04/2008)
7. Held, Claes: 3 articles (05/2014 - 10/2010)
8. Stewart, Ralph: 3 articles (05/2014 - 10/2010)
9. Wallentin, Lars: 3 articles (05/2014 - 10/2010)
10. White, Harvey: 3 articles (08/2013 - 07/2010)

Related Diseases

1. Atherosclerosis
2. Coronary Disease (Coronary Heart Disease)
3. Acute Coronary Syndrome
4. Atherosclerotic Plaque (Atheroma)
5. Myocardial Infarction

Related Drugs and Biologics

1. 1-Alkyl-2-acetylglycerophosphocholine Esterase (PAF Acetylhydrolase)
2. Methotrexate (Mexate)
3. canakinumab
4. Colchicine
5. varespladib
6. Secretory Phospholipases A2
7. Phospholipases (Phospholipase)
8. Phospholipases A2 (Phospholipase A2)
9. Amlodipine (Norvasc)
10. Biological Markers (Surrogate Marker)

Related Therapies and Procedures

1. Stents